O. Abdel-rahman, A. Lamarca, J. W. Valle, and R. A. Hubner, Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations, Endocr Relat Cancer, vol.21, pp.485-493, 2014.
DOI : 10.1530/erc-14-0389

URL : http://erc.endocrinology-journals.org/content/21/6/R485.full.pdf

V. Ambrosini, M. Fani, S. Fanti, F. Forrer, and H. R. Maecke, Radiopeptide imaging and therapy in Europe, J Nucl Med, vol.52, issue.2, pp.42-55, 2011.
DOI : 10.2967/jnumed.110.085753

URL : http://jnm.snmjournals.org/content/52/Supplement_2/42S.full.pdf

M. Annunziata, R. M. Luque, M. Durán-prado, A. Baragli, C. Grande et al., Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility, Hum Reprod, vol.27, pp.2117-2129, 2012.
DOI : 10.1093/humrep/des144

URL : https://academic.oup.com/humrep/article-pdf/27/7/2117/2397206/des144.pdf

F. Bielle, F. Ducray, K. Mokhtari, C. Dehais, H. Adle-biassette et al., Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas, Brain Pathol, vol.27, pp.567-579, 2017.
DOI : 10.1111/bpa.12434

URL : https://hal.archives-ouvertes.fr/hal-01395265

L. Bodei, J. Mueller-brand, R. P. Baum, M. E. Pavel, D. Hörsch et al., The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours, 2013.

, Eur J Nucl Med Mol Imaging, vol.40, pp.800-816

R. L. Bowman, Q. Wang, A. Carro, R. Verhaak, and M. Squatrito, GlioVis data portal for visualization and analysis of brain tumor expression datasets, Neuro-Oncology, vol.19, pp.139-141, 2017.

J. D. Cahoy, B. Emery, A. Kaushal, L. C. Foo, J. L. Zamanian et al., A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function, J Neurosci, vol.28, pp.264-278, 2008.

C. Network, D. J. Brat, R. V. Aldape, K. D. , W. Y. Salama et al., Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas, N Engl J Med, vol.372, pp.2481-2498, 2015.

O. Casar-borota, A. Heck, S. Schulz, J. M. Nesland, J. Ramm-pettersen et al., Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide, J Clin Endocrinol Metab, vol.98, pp.1730-1739, 2013.

F. Ducray, A. Idbaih, A. De-reyniès, I. Bièche, J. Thillet et al., Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile, Mol Cancer, vol.7, p.41, 2008.

A. Dutour, U. Kumar, R. Panetta, L. Ouafik, F. Fina et al., Expression of somatostatin receptor subtypes in human brain tumors, Int J Cancer, vol.76, pp.620-627, 1998.

D. Figarella-branger, K. Mokhtari, C. Dehais, A. Jouvet, E. Uro-coste et al., Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations, Neuro-Oncology, vol.16, pp.1244-1254, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01627027

T. Florio, Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors, Front Biosci, vol.13, pp.822-840, 2008.

F. Gatto and L. J. Hofland, The role of somatostatin and dopamine D2 receptors in endocrine tumors, Endocr Relat Cancer, vol.18, pp.233-251, 2011.

D. Heute, H. Kostron, E. Von-guggenberg, S. Ingorokva, M. Gabriel et al., Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC, J Nucl Med, vol.51, pp.397-400, 2010.

H. S. Kim, H. S. Lee, and W. H. Kim, Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors, Cancer Res Treat, vol.43, pp.181-188, 2011.

A. Kiviniemi, M. Gardberg, K. Kivinen, J. P. Posti, V. Vuorinen et al., Somatostatin receptor 2A in gliomas: association with oligodendrogliomas and favourable outcome, Oncotarget, vol.8, p.49123, 2017.
DOI : 10.18632/oncotarget.17097

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=17097&path%5B%5D=54714

L. Krulich, A. P. Dhariwal, and S. M. Mccann, Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro, Endocrinology, vol.83, pp.783-790, 1968.

Y. Liu, L. Jiang, and Y. Mu, Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment, Oncol Lett, vol.6, pp.821-828, 2013.

D. N. Louis, A. Perry, G. Reifenberger, V. Deimling, A. Figarella-branger et al., The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol, vol.131, pp.803-820, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

C. Mawrin, S. Schulz, S. U. Pauli, T. Treuheit, S. Diete et al., Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas, J Neuropathol Exp Neurol, vol.63, pp.13-19, 2004.

A. Merlo, O. Hausmann, M. Wasner, P. Steiner, A. Otte et al., Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3octreotide (DOTATOC): a pilot study in human gliomas, Clin Cancer Res, vol.5, pp.1025-1033, 1999.

K. Okuwaki, M. Kida, T. Mikami, H. Yamauchi, H. Imaizumi et al., Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes, Cancer, vol.119, pp.4094-4102, 2013.

S. Pola, M. G. Cattaneo, and L. M. Vicentini, Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity, J Biol Chem, vol.278, pp.40601-40606, 2003.

C. C. Raggi, M. Maggi, D. Renzi, A. Calabrò, M. L. Bagnoni et al., Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome, J Clin Endocrinol Metab, vol.85, pp.3866-3873, 2000.

J. C. Reubi and A. Schonbrunn, Illuminating somatostatin analog action at neuroendocrine tumor receptors, Trends Pharmacol Sci, vol.34, pp.676-688, 2013.

T. Schumacher, S. Hofer, K. Eichhorn, M. Wasner, S. Zimmerer et al., Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study, Eur J Nucl Med Mol Imaging, vol.29, pp.486-493, 2002.

K. B. Song, S. C. Kim, J. H. Kim, D. Seo, S. Hong et al., Prognostic value of somatostatin receptor subtypes in pancreatic neuroendocrine tumors, Pancreas, vol.45, pp.187-192, 2016.

J. Strosberg, G. El-haddad, E. Wolin, A. Hendifar, J. Yao et al., Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors, N Engl J Med, vol.376, pp.125-135, 2017.

E. Tabouret, A. T. Nguyen, C. Dehais, C. Carpentier, F. Ducray et al., Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort, Acta Neuropathol, vol.132, pp.625-634, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01480146

X. Tang, S. Takekoshi, J. Itoh, S. Umemura, S. Shoji et al., Somatostatin analogue inhibits the mobility of prostate carcinoma cells: a new therapeutic method for advanced prostate carcinoma, Int J Oncol, vol.37, pp.1077-1083, 2010.

M. Theodoropoulou and G. K. Stalla, Somatostatin receptors: from signaling to clinical practice, Front Neuroendocrinol, vol.34, pp.228-252, 2013.

R. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, vol.17, pp.98-110, 2010.

E. Vitali, V. Cambiaghi, A. Zerbi, C. Carnaghi, P. Colombo et al., Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours, Endocr Relat Cancer, vol.23, pp.181-190, 2016.

M. Vyberg, B. P. Ulhøi, and P. S. Teglbjaerg, Neuronal features of oligodendrogliomas-an ultrastructural and immunohistochemical study, Histopathology, vol.50, pp.887-896, 2007.

M. Weller, M. Van-den-bent, J. C. Tonn, R. Stupp, M. Preusser et al., European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncol, vol.18, pp.315-329, 2017.

H. Yan, D. W. Parsons, J. G. Mclendon, R. Rasheed, B. A. Yuan et al., IDH1 and IDH2 mutations in gliomas, N Engl J Med, vol.360, pp.765-773, 2009.